CN102939090A - miRNA-29表达拮抗剂及其在预防和治疗主动脉瘤中的用途 - Google Patents

miRNA-29表达拮抗剂及其在预防和治疗主动脉瘤中的用途 Download PDF

Info

Publication number
CN102939090A
CN102939090A CN2011800172888A CN201180017288A CN102939090A CN 102939090 A CN102939090 A CN 102939090A CN 2011800172888 A CN2011800172888 A CN 2011800172888A CN 201180017288 A CN201180017288 A CN 201180017288A CN 102939090 A CN102939090 A CN 102939090A
Authority
CN
China
Prior art keywords
mirna
antagonist
expression
aortic
aortic aneurysm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800172888A
Other languages
English (en)
Chinese (zh)
Inventor
安德里亚斯·察赫尔
斯特凡妮·迪梅勒
雷耶尔·布恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe Universitaet Frankfurt am Main
Original Assignee
Goethe Universitaet Frankfurt am Main
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe Universitaet Frankfurt am Main filed Critical Goethe Universitaet Frankfurt am Main
Publication of CN102939090A publication Critical patent/CN102939090A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2011800172888A 2010-04-01 2011-04-01 miRNA-29表达拮抗剂及其在预防和治疗主动脉瘤中的用途 Pending CN102939090A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10003675.5 2010-04-01
EP10003675A EP2371370A1 (en) 2010-04-01 2010-04-01 Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization
PCT/EP2011/055122 WO2011121120A1 (en) 2010-04-01 2011-04-01 ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS

Publications (1)

Publication Number Publication Date
CN102939090A true CN102939090A (zh) 2013-02-20

Family

ID=42269707

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800172888A Pending CN102939090A (zh) 2010-04-01 2011-04-01 miRNA-29表达拮抗剂及其在预防和治疗主动脉瘤中的用途

Country Status (9)

Country Link
US (1) US9062307B2 (enExample)
EP (2) EP2371370A1 (enExample)
JP (2) JP6224455B2 (enExample)
CN (1) CN102939090A (enExample)
AU (1) AU2011234453B2 (enExample)
CA (1) CA2795164C (enExample)
ES (1) ES2690198T3 (enExample)
RU (1) RU2012146518A (enExample)
WO (1) WO2011121120A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214949A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种抑制 miRNA-29a 表达的慢病毒载体的构建及其应用
WO2017219170A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
WO2017219169A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 一种抑制 miRNA-29a 和 miR-185 表达的慢病毒载体及其应用
CN109762883A (zh) * 2019-01-31 2019-05-17 温州医科大学 血浆/血清外泌体hsa-miRNA-29-3p作为青光眼诊断标志物中的应用
CN114432453A (zh) * 2022-02-25 2022-05-06 上海大学 敲低或抑制clec4d的试剂在制备心肌缺血再灌注损伤药物中的应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US8618073B2 (en) 2010-07-22 2013-12-31 The University Of North Carolina At Chapel Hill Use of miR-29 for cell protection
JP2015518475A (ja) * 2012-04-10 2015-07-02 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 非アルコール性脂肪性肝炎の治療方法
EP2861238A4 (en) 2012-06-05 2016-03-16 Capricor Inc OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
RU2712511C2 (ru) * 2014-09-08 2020-01-29 Мираген Терапеутикс, Инк. Миметики mir-29 и пути их применения
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3247716A4 (en) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
CN110511930B (zh) * 2019-06-11 2023-01-10 河北医科大学 Sal-miR-58及其在抑制血管炎性反应和动脉瘤形成中的用途
CN117979975A (zh) * 2021-05-07 2024-05-03 加利福尼亚大学董事会 用于预防和治疗动脉瘤、高血压、ards和其他与内皮功能障碍相关联的疾病的mirna抑制剂
US20250304956A1 (en) * 2021-08-06 2025-10-02 Leadermed Champion Limited miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018493A1 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System A micro-rna family that modulates fibrosis and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (en) 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
CL2008003699A1 (es) * 2007-12-13 2009-10-09 Takeda Pharmaceuticals Co Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas.
CA2716343A1 (en) * 2008-02-21 2009-08-27 The Board Of Regents Of The University Of Texas System Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018493A1 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System A micro-rna family that modulates fibrosis and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JONATHAN GOLLEDGE等: "Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm", 《ATHEROSCLEROSIS》 *
YUMEI YE等: "Downregulation of microRNA-29 by antisense inhibitors and a PPAR-γ agonist protects against myocardial ischaemia-reperfusion injury", 《CARDIOVASCULAR RESEARCH》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214949A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种抑制 miRNA-29a 表达的慢病毒载体的构建及其应用
WO2017219170A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
WO2017219169A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 一种抑制 miRNA-29a 和 miR-185 表达的慢病毒载体及其应用
CN109762883A (zh) * 2019-01-31 2019-05-17 温州医科大学 血浆/血清外泌体hsa-miRNA-29-3p作为青光眼诊断标志物中的应用
CN114432453A (zh) * 2022-02-25 2022-05-06 上海大学 敲低或抑制clec4d的试剂在制备心肌缺血再灌注损伤药物中的应用
CN114432453B (zh) * 2022-02-25 2022-10-14 上海大学 敲低或抑制clec4d的试剂在制备心肌缺血再灌注损伤药物中的应用

Also Published As

Publication number Publication date
US9062307B2 (en) 2015-06-23
EP2552454A1 (en) 2013-02-06
US20130116303A1 (en) 2013-05-09
ES2690198T3 (es) 2018-11-19
CA2795164A1 (en) 2011-10-06
JP6224455B2 (ja) 2017-11-01
EP2371370A1 (en) 2011-10-05
RU2012146518A (ru) 2014-05-10
JP2016193888A (ja) 2016-11-17
CA2795164C (en) 2019-06-18
EP2552454B1 (en) 2018-07-11
AU2011234453A1 (en) 2012-10-18
WO2011121120A1 (en) 2011-10-06
JP2013523696A (ja) 2013-06-17
AU2011234453B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
CN102939090A (zh) miRNA-29表达拮抗剂及其在预防和治疗主动脉瘤中的用途
Denby et al. miR-21 and miR-214 are consistently modulated during renal injury in rodent models
JP5898843B2 (ja) 血管新生、血管形成、若しくは血管修復を促進するか、又は腫瘍血管新生を阻害する方法
CA2977624C (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
US7994150B2 (en) Micro-RNAs that modulate smooth muscle proliferation and differentiation and uses thereof
JP5960060B2 (ja) 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
US9320756B2 (en) UCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis
EP2228444A1 (en) microRNA for diagnostic and therapeutic purposes in cardiovascular diseases
KR20100049079A (ko) 인간의 정상 심장과 기능부진 심장에서 마이크로 ｒｎａ의 차등 발현
CN107267625B (zh) lncRNA作为生物标志物在肝癌诊疗中的用途
EP2298359A1 (en) Nucleic acid capable of controlling degranulation of mast cell
SG190355A1 (en) Microrna inhibitors comprising locked nucleotides
JP2013511964A (ja) ｍｉＲＮＡ−１００を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用
JP5522435B2 (ja) Ｍｘｄ３遺伝子の発現阻害による肥満の抑制
CN102266569B (zh) miR-199a及其抑制剂的应用
US10287633B2 (en) TYRP1, a natural miRNA sponge, and its use in managing human melanoma aggressiveness
JP7654204B2 (ja) ８－オキソグアニンを含むｒｎａ干渉誘導核酸、８－オキソグアニンを含むマイクロｒｎａと結合する修飾核酸およびこれらの使用
Preethi et al. Therapeutic aspect of microRNA inhibition in various types of hypertension and hypertensive complications
CN120464740B (zh) Usp21在腹主动脉瘤诊治中的应用
KR20150078074A (ko) microRNA-365 활성화제를 포함하는 혈관평활근세포 증식 또는 이동 억제용 약학적 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130220